2004 ACC/AHA guideline for the management of patients with STEMI: The implications for clinicians

Nature Clinical Practice Cardiovascular Medicine

Volumn 2, Issue 3, 2005, Pages 114-115

  Giugliano, Robert P ^a,b   Braunwald, Eugene ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Brigham and Women's Hospital ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CANDESARTAN; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HORMONE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; RENIN ANGIOTENSION ALDOSTERONE INHIBITOR; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; VALSARTAN;

ACUTE HEART INFARCTION; ADJUVANT THERAPY; BLEEDING; CARDIOGENIC SHOCK; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY STENT; DEFIBRILLATOR; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELUTING STENT; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FIBRINOLYTIC THERAPY; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; MEDICAL SOCIETY; META ANALYSIS; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; ST SEGMENT ELEVATION; SYSTEMATIC REVIEW; TREATMENT INDICATION;

CORONARY ANGIOGRAPHY; ELECTROCARDIOGRAPHY; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; THROMBOLYTIC THERAPY;

EID: 20444497918     PISSN: 17434297     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncpcardio0135     Document Type: Review

References (10)

1. Antman EM et al. (2004) ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol 44: E1-E211
2. Keeley EC et al. (2003) Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361: 13-20
3. Hochman JS et al. (2001) One-year survival following early revascularization for cardiogenic shock. JAMA 285: 190-192
4. Moss AJ et al. (2002) Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346: 877-883
5. Lee KL et al. (2002) Effect of implantable defibrillators on arrhythmic events and mortality in the multicenter unsustained tachycardia trial. Circulation 106: 233-238
6. Yusuf S et al. (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345: 494-502
7. Karvouni E et al. (2003) Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol 41: 26-32
8. Pfeffer MA et al. (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349: 1893-1906
9. Granger CB et al. (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362: 772-776
10. Pitt B et al. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309-1321